Cargando…

Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease

We previously demonstrated that pretreatment with Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist, reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) –mediated dopaminergic neurodegeneration. The use of GLP-1 or Exendin-4 for Parkinson’s disease (PD) patients is limited by the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Shuchun, Yu, Seong-Jin, Li, Yazhou, Lecca, Daniela, Glotfelty, Elliot, Kim, Hee Kyung, Choi, Ho-Il, Hoffer, Barry J., Greig, Nigel H., Kim, Dong Seok, Wang, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048117/ https://www.ncbi.nlm.nih.gov/pubmed/30013201 http://dx.doi.org/10.1038/s41598-018-28449-z

Ejemplares similares

Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
por: Chen, Shuchun, et al.
Publicado: (2018)

PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease
por: Yu, Seong-Jin, et al.
Publicado: (2020)

Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats
por: Eakin, Katharine, et al.
Publicado: (2013)

Abrogation of the Circadian Nuclear Receptor REV-ERBα Exacerbates 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration
por: Kim, Jeongah, et al.
Publicado: (2018)

Prosaposin PS18 reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinson’s disease
por: Wu, Kuo-Jen, et al.
Publicado: (2023)

Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration
por: Rachmany, Lital, et al.
Publicado: (2017)

(−)‐Phenserine tartrate (PhenT) as a treatment for traumatic brain injury
por: Greig, Nigel H., et al.
Publicado: (2019)

The RhoA-ROCK1/ROCK2 Pathway Exacerbates Inflammatory Signaling in Immortalized and Primary Microglia
por: Glotfelty, Elliot J., et al.
Publicado: (2023)

Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis
por: Lecca, Daniela, et al.
Publicado: (2022)

Both Intracranial and Intravenous Administration of Functionalized Carbon Nanotubes Protect Dopaminergic Neuronal Death from 6-Hydroxydopamine
por: Kim, Ok-Hyeon, et al.
Publicado: (2020)

Alleviation of Methamphetamine Sensitization by Partially Lesioning Dopaminergic Terminals with 6-Hydroxydopamine in Nucleus Accumbens
por: Chen, Shu-Chun, et al.
Publicado: (2021)

3,6′-Dithiopomalidomide Ameliorates Hippocampal Neurodegeneration, Microgliosis and Astrogliosis and Improves Cognitive Behaviors in Rats with a Moderate Traumatic Brain Injury
por: Huang, Pen-Sen, et al.
Publicado: (2021)

Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis
por: Li, Yazhou, et al.
Publicado: (2012)

Achyranthes bidentata polypeptide protects dopaminergic neurons from apoptosis induced by rotenone and 6-hydroxydopamine
por: Peng, Su, et al.
Publicado: (2018)

Protective Effect of Amber Extract on Human Dopaminergic Cells against 6-Hydroxydopamine-Induced Neurotoxicity
por: Luo, Yuening, et al.
Publicado: (2022)

Genetic Defects in Mitochondrial Dynamics in Caenorhabditis elegans Impact Ultraviolet C Radiation- and 6-hydroxydopamine-Induced Neurodegeneration
por: Hartman, Jessica H., et al.
Publicado: (2019)

Destruction of Dopaminergic Neurons in the Midbrain by 6-Hydroxydopamine Decreases Hippocampal Cell Proliferation in Rats: Reversal by Fluoxetine
por: Suzuki, Katsuaki, et al.
Publicado: (2010)

Erythropoietin improves neurobehavior by reducing dopaminergic neuron loss in a 6-hydroxydopamine-induced rat model
por: QI, CHEN, et al.
Publicado: (2014)

Sorbus alnifolia protects dopaminergic neurodegeneration in Caenorhabditis elegans
por: Cheon, Se-Myeong, et al.
Publicado: (2016)

Suppression of 6-Hydroxydopamine-Induced Oxidative Stress by Hyperoside Via Activation of Nrf2/HO-1 Signaling in Dopaminergic Neurons
por: Kwon, Seung-Hwan, et al.
Publicado: (2019)

Neurturin overexpression in dopaminergic neurons induces presynaptic and postsynaptic structural changes in rats with chronic 6-hydroxydopamine lesion
por: Reyes-Corona, David, et al.
Publicado: (2017)

Modafinil Improves Catalepsy in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease; Possible Involvement of Dopaminergic Neurotransmission
por: Vajdi-Hokmabad, Reza, et al.
Publicado: (2017)

NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson’s disease
por: Cheng, Li, et al.
Publicado: (2018)

Nanofiber matrix formulations for the delivery of Exendin-4 for tendon regeneration: In vitro and in vivo assessment
por: Abdulmalik, Sama, et al.
Publicado: (2023)

Neuroprotective Effects of Erucin against 6-Hydroxydopamine-Induced Oxidative Damage in a Dopaminergic-like Neuroblastoma Cell Line
por: Tarozzi, Andrea, et al.
Publicado: (2012)

Dopaminergic neurons show increased low-molecular-mass protein 7 activity induced by 6-hydroxydopamine in vitro and in vivo
por: Mo, Ming-Shu, et al.
Publicado: (2018)

Investigating Bacterial Sources of Toxicity as an Environmental Contributor to Dopaminergic Neurodegeneration
por: Caldwell, Kim A., et al.
Publicado: (2009)

Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon
por: Li, Yazhou, et al.
Publicado: (2019)

Exposure to Mitochondrial Genotoxins and Dopaminergic Neurodegeneration in Caenorhabditis elegans
por: González-Hunt, Claudia P., et al.
Publicado: (2014)

The Role of Autophagy Dysregulation in Manganese-Induced Dopaminergic Neurodegeneration
por: Zhang, Jianbin, et al.
Publicado: (2013)

Epothilone B Benefits Nigral Dopaminergic Neurons by Attenuating Microglia Activation in the 6-Hydroxydopamine Lesion Mouse Model of Parkinson’s Disease
por: Yu, Zhongyuan, et al.
Publicado: (2018)

Protective effect of hydroxysafflor yellow A on dopaminergic neurons against 6-hydroxydopamine, activating anti-apoptotic and anti-neuroinflammatory pathways
por: Yang, Xiaomei, et al.
Publicado: (2020)

Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson’s disease
por: Chen, Weizhao, et al.
Publicado: (2022)

Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model
por: Zhang, Ling-Yu, et al.
Publicado: (2021)

miRNA-302s may act as oncogenes in human testicular germ cell tumours
por: Das, Mrinal K., et al.
Publicado: (2019)

Exendin-4 for Parkinson's disease
por: Esparza-Salazar, Felipe de Jesús, et al.
Publicado: (2021)

Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine
por: Ando, Kiyoshi, et al.
Publicado: (2017)

Application of the Physical Disector Principle for Quantification of Dopaminergic Neuronal Loss in a Rat 6-Hydroxydopamine Nigral Lesion Model of Parkinson's Disease
por: Fabricius, Katrine, et al.
Publicado: (2017)

The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy
por: Rodríguez-Carreiro, Santiago, et al.
Publicado: (2023)

Erratum to: The Role of Autophagy Dysregulation in Manganese-Induced Dopaminergic Neurodegeneration
por: Zhang, Jianbin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tbsue1cvjogn28mao1r700vfms